A meeting entitled, “Interferon Lambda: Disease Impact and Translational Potential,” was held on the campus of the National Institutes of Health in Bethesda, Maryland, on October 25–26, 2018. To our knowledge, this was the first meeting that focused exclusively on interferon lambda (IFN-λ). The meeting's purpose was to enhance interdisciplinary communication and promote new collaborations. The gathering brought together an international group of scientists from a wide range of disciplines. Sessions included: IFN-λ Biology, Therapy and Genetic Variation; IFN-λ and Hepatitis C Virus Infection; IFN-λ in Other Infections; and IFN-λ—Hepatic Fibrosis and Cancer. The next meeting on IFN-λ is planned for 2020.
Get full access to this article
View all access options for this article.
References
1.
AkaPV, KuniholmMH, PfeifferRM, WangAS, TangW, ChenS, AstemborskiJ, PlankeyM, VillacresMC, PetersMG, DesaiS, SeabergEC, EdlinBR, StricklerHD, ThomasDL, Prokunina-OlssonL, SharpGB, O'BrienTR. 2014. Association of the IFNL4-ΔG allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis, 209:350–354.
BayerA, LennemannNJ, OuyangY, BramleyJC, MoroskyS, MarquesET, CherryS, SadovskyY, CoyneCB. 2016. Type III interferons produced by human placental trophoblasts confer protection against zika virus infection. Cell Host Microbe, 19:705–712.
4.
ChanHLY, AhnSH, ChangT-T, PengC-Y, WongD, CoffinCS, LimSG, ChenP-J, JanssenHLA, MarcellinP, SerfatyL, ZeuzemS, CohenD, CritelliL, XuD, Wind-RotoloM, CooneyE. 2016. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B). J Hepatol, 64:1011–1019.
5.
DonnellyRP, KotenkoSV. 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res, 30:555–564.
6.
EslamM, HashemAM, LeungR, Romero-GomezM, BergT, DoreGJ, ChanHLK, IrvingWL, SheridanD, AbateML, AdamsLA, MangiaA, WeltmanM, BugianesiE, SpenglerU, ShakerO, FischerJ, MollisonL, ChengW, PowellE, NattermannJ, RiordanS, McleodD, ArmstrongNJ, DouglasMW, LiddleC, BoothDR, GeorgeJ, AhlenstielG, The International HepatitisCGC. 2015. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun, 6:6422.
7.
EspinosaV, DuttaO, McelrathC, DuP, ChangY-J, CicciarelliB, PitlerA, WhiteheadI, ObarJJ, DurbinJE, KotenkoSV, RiveraA. 2017. Type III interferon is a critical regulator of innate antifungal immunity. Sci Immunol, 2:eaan5357.
KelemenLE, LawrensonK, TyrerJ, LiQ, LeeJM, SeoJH, PhelanCM, BeesleyJ, ChenX, SpindlerTJ, AbenKK, Anton-CulverH, AntonenkovaN, Australian CancerS, Australian Ovarian Cancer StudyG, Ovarian Cancer AssociationC. 2015. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet, 47:888–897.
11.
KeyFM, PeterB, DennisMY, Huerta-SanchezE, TangW, Prokunina-OlssonL, NielsenR, AndresAM. 2014. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet, 10:e1004681.
12.
KotenkoSV, GallagherG, BaurinVV, Lewis-AntesA, ShenM, ShahNK, LangerJA, SheikhF, DickensheetsH, DonnellyRP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 4:69–77.
13.
LazearHM, DanielsBP, PintoAK, HuangAC, VickSC, DoyleSE, GaleM, KleinRS, DiamondMS. 2015a. Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci Transl Med, 7:284ra59–284ra59.
14.
LazearHM, NiceTJ, DiamondMS. 2015b. Interferon-λ: immune Functions at Barrier Surfaces and Beyond. Immunity, 43:15–28.
15.
MeissnerEG, BonD, Prokunina-OlssonL, TangW, MasurH, O'BrienTR, HerrmannE, KottililS, OsinusiA. 2014. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis, 209:1700–1704.
16.
MinasTZ, TangW, SmithCJ, OnabajoOO, ObajemuA, DorseyTH, JordanSV, ObadiOM, RyanBM, Prokunina-OlssonL, LoffredoCA, AmbsS. 2018. IFNL4-DeltaG is associated with prostate cancer among men at increased risk of sexually transmitted infections. Commun Biol, 1:191.
17.
MuirAJ, AroraS, EversonG, FlisiakR, GeorgeJ, GhalibR, GordonSC, GrayT, GreenbloomS, HassaneinT, HillsonJ, HorgaMA, JacobsonIM, JeffersL, KowdleyKV, LawitzE, LuethS, Rodriguez-TorresM, RustgiV, ShemanskiL, ShiffmanML, SrinivasanS, VargasHE, VierlingJM, XuD, Lopez-TalaveraJC, ZeuzemS. 2014. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol, 61:1238–1246.
18.
MuirAJ, ShiffmanML, ZamanA, YoffeB, de la TorreA, FlammS, GordonSC, MarottaP, VierlingJM, Lopez-TalaveraJC, Byrnes-BlakeK, FontanaD, FreemanJ, GrayT, HausmanD, HunderNN, LawitzE. 2010. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology, 52:822–832.
19.
NiceTJ, BaldridgeMT, MccuneBT, NormanJM, LazearHM, ArtyomovM, DiamondMS, VirginHW. 2015. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science, 347:269–273.
O'BrienTR. 2009. Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet, 41:1048–1050.
22.
O'BrienTR, KottililS, FeldJJ, MorganTR, PfeifferRM. 2017a. Race or genetic makeup for hepatitis C virus treatment decisions?. Hepatology, 65:2124–2125.
23.
O'BrienTR, KottililS, PfeifferRM. 2017b. IFNL4 genotype is associated with virologic relapse after 8-week treatment with sofosbuvir, velpatasvir, and voxilaprevir. Gastroenterology, 153:1694–1695.
24.
O'BrienTR, PfeifferRM, PaquinA, Lang KuhsKA, ChenS, BonkovskyHL, EdlinBR, HowellCD, KirkGD, KuniholmMH, MorganTR, StricklerHD, ThomasDL, Prokunina-OlssonL. 2015. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol, 63:1103–1110.
25.
OdendallC, VoakAA, KaganJC. 2017. Type III IFNs are commonly induced by bacteria-sensing TLRs and reinforce epithelial barriers during infection. J Immunol, 199:3270–3279.
26.
PettaS, ValentiL, TuttolomondoA, DongiovanniP, PipitoneRM, CammàC, CabibiD, Di MarcoV, FracanzaniAL, BadialiS, NobiliV, FargionS, GrimaudoS, CraxìA. 2017. Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology, 66:1885–1893.
27.
Prokunina-OlssonL, MuchmoreB, TangW, PfeifferRM, ParkH, DickensheetsH, HergottD, Porter-GillP, MumyA, KohaarI, ChenS, BrandN, TarwayM, LiuL, SheikhF, AstemborskiJ, BonkovskyHL, EdlinBR, HowellCD, MorganTR, ThomasDL, RehermannB, DonnellyRP, O'BrienTR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet, 45:164–171.
28.
SchnepfD, StaeheliP. 2017. License to kill: IFN-λ regulates antifungal activity of neutrophils. Sci Immunol, 2:eaap9614.
29.
SheppardP, KindsvogelW, XuW, HendersonK, SchlutsmeyerS, WhitmoreTE, KuestnerR, GarriguesU, BirksC, RorabackJ, OstranderC, DongD, ShinJ, PresnellS, FoxB, HaldemanB, CooperE, TaftD, GilbertT, GrantFJ, TackettM, KrivanW, McknightG, CleggC, FosterD, KlucherKM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 4:63–68.
30.
SuppiahV, MoldovanM, AhlenstielG, BergT, WeltmanM, AbateML. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet, 41(10):1100–1104.
31.
TanakaY, NishidaN, SugiyamaM, KurosakiM, MatsuuraK, SakamotoN. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet, 41(10):1105–1109.
32.
TangW, WallaceTA, YiM, Magi-GalluzziC, DorseyTH, OnabajoOO, ObajemuA, JordanSV, LoffredoCA, StephensRM, SilvermanRH, StarkGR, KleinEA, Prokunina-OlssonL, AmbsS. 2018. IFNL4-DeltaG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer. Clin Cancer Res, 24:5471–5481.
